Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 

Similar presentations


Presentation on theme: "A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data "— Presentation transcript:

1 A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data  Hind T. Hatoum, Ph.D., William R. Keye, M.D., Richard P. Marrs, M.D., Surrey M. Walton, Ph.D., Dennis C. Marshall, R.N., M.S., Ph.D.  Fertility and Sterility  Volume 83, Issue 3, Pages (March 2005) DOI: /j.fertnstert Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

2 FIGURE 1 Outline of Markov model illustrating transition between health states for each treatment cycle. OHSS = ovarian hyperstimulation syndrome. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions


Download ppt "A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data "

Similar presentations


Ads by Google